Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582217 · ClinicalTrials.gov registry record
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 318
- Enrollment target
NCT01582217 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 318 participants.
The verdict
NCT01582217 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 318 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that includes both clinical risks and platelet reactivity while on chronic clopidogrel therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582217
The ClinicalTrials.gov registry entry for NCT01582217 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01582217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582217 about?
NCT01582217 is a clinical study titled "Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition". The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that includes both clinical risks and platelet reactivity while on chronic clopidog...
What is the current status of trial NCT01582217?
This trial is currently completed. The enrollment target is 318 participants. The study started on 2012-03. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01582217?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.